Sharpepoint LLC bought a new position in shares of Organon & Co. (NYSE:OGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 42,149 shares of the company's stock, valued at approximately $629,000.
Several other large investors also recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB grew its position in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares in the last quarter. Treasurer of the State of North Carolina increased its position in shares of Organon & Co. by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company's stock valued at $1,688,000 after purchasing an additional 710 shares during the last quarter. Beam Wealth Advisors Inc. increased its position in shares of Organon & Co. by 3.9% in the 4th quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company's stock valued at $282,000 after purchasing an additional 717 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Organon & Co. by 0.5% in the 4th quarter. HighTower Advisors LLC now owns 163,440 shares of the company's stock valued at $2,439,000 after purchasing an additional 855 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of Organon & Co. by 4.9% during the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock worth $381,000 after purchasing an additional 1,184 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Morgan Stanley dropped their price objective on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Finally, TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $20.60.
Check Out Our Latest Stock Analysis on OGN
Organon & Co. Stock Performance
Shares of OGN stock traded up $0.63 during mid-day trading on Thursday, hitting $12.12. 5,999,755 shares of the stock were exchanged, compared to its average volume of 2,706,162. The stock's fifty day simple moving average is $13.99 and its two-hundred day simple moving average is $15.27. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 12-month low of $10.45 and a 12-month high of $23.10. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of 3.64, a P/E/G ratio of 0.90 and a beta of 0.73.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, analysts forecast that Organon & Co. will post 3.68 EPS for the current year.
Organon & Co. Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.24%. Organon & Co.'s payout ratio is 33.63%.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
